Pancreatic Adenocarcinoma Clinical Trial
— APACHOfficial title:
PAncreatic Adenocarcinoma in Hospital
| NCT number | NCT01989624 |
| Other study ID # | CHD064-13 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 18, 2013 |
| Est. completion date | December 2020 |
| Verified date | March 2022 |
| Source | Centre Hospitalier Departemental Vendee |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%. Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life. The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country. The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.
| Status | Completed |
| Enrollment | 1204 |
| Est. completion date | December 2020 |
| Est. primary completion date | December 4, 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Living in France - Pancreatic adenocarcinoma histologically or cytologically proven - primary diagnosis - Agreed to participate Exclusion Criteria: - Suspected pancreatic adenocarcinoma histologically or cytologically unproven - Refused to participate |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | CH de Jolimont | Jolimont | |
| France | CHIAP | Aix en Provence | |
| France | CH Angoulême | Angoulême | |
| France | CH d'Aubenas | Aubenas | |
| France | CH Auch | Auch | |
| France | CH Robert Ballanger | Aulnay sous bois | |
| France | CH Avignon | Avignon | |
| France | CH Bagnols sur Ceze | Bagnols sur Ceze | |
| France | CH Bayeux | Bayeux | |
| France | CH Béziers | Béziers | |
| France | CH Blois | Blois | |
| France | CH Bourg en Bresse | Bourg en Bresse | |
| France | CH de Bourges | Bourges | |
| France | CH Nord Deux Sèvres | Bressuire | |
| France | CH Saint Camille | Bry sur Marne | |
| France | HPA Castres Mazamet | Castres | |
| France | CH Chalons en champagne | Chalons en champagne | |
| France | CH Chambery | Chambery | |
| France | CH Chartres | Chartres | |
| France | CH Haut Anjou | Château Gontier | |
| France | CH Châteauroux | Châteauroux | |
| France | Ch Cholet | Cholet | |
| France | CH Compiègne Noyon | Compiègne | |
| France | CH sud francilien | Corbeil Essonnes | |
| France | CH de Creil | Creil | |
| France | CHI Créteil | Créteil | |
| France | CH Dourdan | Dourdan | |
| France | CH Draguignan | Draguignan | |
| France | CH Dreux | Dreux | |
| France | CH Simone Veil | Eaubonne | |
| France | CH Forcilles | Ferolles | |
| France | Chicas | Gap | |
| France | CH Gonesse | Gonesse | |
| France | Centre hospitalier départemental Vendée | La Roche sur Yon | |
| France | Centre Hospitalier de Lagny | Lagny sur Marne | |
| France | CH du Mans | Le Mans | |
| France | Lens | Lens | |
| France | Centre Hospitalier Côté de lumière | Les Sables d'Olonne | |
| France | Hôpital des chanaux | Macon | |
| France | Centre Hospitalier de Meaux | Meaux | |
| France | CH Melun | Melun | |
| France | CHR de Mercy-Metz | Metz | |
| France | CHAM | Montargis | |
| France | CH Montauban | Montauban | |
| France | Centre Hospitalier Montelimar | Montelimar | |
| France | CH Montfermeil | Montfermeil | |
| France | CH Niort | Niort | |
| France | CHG Oloron | Oloron Sainte Marie | |
| France | CHR Orléans | Orléans | |
| France | CH François Mitterand | Pau | |
| France | Centre Hospitalier de Perpignan | Perpignan | |
| France | CHI Poissy Saint Germain | Poissy | |
| France | CH Pontoise | Pontoise | |
| France | CH de la région d'Annecy | Pringy | |
| France | CH Quimper | Quimper | |
| France | CH Roubaix | Roubaix | |
| France | Centre hospitalier Yves Le Foll | Saint Brieuc | |
| France | CH Saint Quentin | Saint Quentin | |
| France | CH de la Fontaine | Saint-Denis | |
| France | CH Gabriel Martin | Saint-Paul | La Réunion |
| France | Centre Hospitalier de Bigorre | Tarbes | |
| France | CH Sainte Musse | Toulon | |
| France | CH Tourcoing | Tourcoing | |
| France | CH Valenciennes | Valenciennes | |
| France | CHBA de Vannes | Vannes | |
| France | CHIV Villeneuve Saint-Georges | Villeneuve Saint-Georges |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Departemental Vendee |
Belgium, France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Survival | patient death (following during 5 year) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03673423 -
Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
|
||
| Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT06026943 -
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer
|
N/A | |
| Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
| Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
| Recruiting |
NCT02072616 -
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
|
Phase 3 | |
| Completed |
NCT02174887 -
Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03703063 -
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
|
Phase 1 | |
| Terminated |
NCT04077372 -
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
|
N/A | |
| Recruiting |
NCT03073785 -
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT03665441 -
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
|
Phase 3 | |
| Recruiting |
NCT04627246 -
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06217666 -
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
|
Phase 1 | |
| Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04119362 -
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
|
||
| Completed |
NCT03105921 -
Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma
|
N/A |